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AbstrACt
Objective To investigate the associations between 
lifestyle and vascular risk factors and changes in 
Alzheimer’s disease (AD) biomarkers (beta-amyloid load 
via 11C-PiB PET, glucose metabolism via 18F-FDG PET 
and neurodegeneration via structural MRI) and global 
cognition in middle-aged asymptomatic participants at 
risk for AD.
Design Prospective, longitudinal.
setting The study was conducted at New York University 
Langone/Weill Cornell Medical Centres in New York City.
Participants Seventy cognitively normal participants 
from multiple community sources, aged 30–60 years 
with lifestyle measures (diet, intellectual activity and 
physical activity), vascular risk measures and two imaging 
biomarkers visits over at least 2 years, were included in 
the study.
Outcome measures We examined MRI-based cortical 
thickness, fluoro-deoxy-glucose (FDG) glucose metabolism 
and PiB beta-amyloid in AD-vulnerable regions. A global 
cognitive z-score served as our summary cognition 
measure. We used regression change models to 
investigate the associations of clinical, lifestyle and 
vascular risk measures with changes in AD biomarkers 
and global cognition.
results Diet influenced changes in glucose metabolism, 
but not amyloid or cortical thickness changes. With and 
without accounting for demographic measures, vascular 
risk and baseline FDG measures, lower adherence to a 
Mediterranean-style diet was associated with faster rates 
of FDG decline in the posterior cingulate cortex (p≤0.05) 
and marginally in the frontal cortex (p=0.07). None of the 
other lifestyle variables or vascular measures showed 
associations with AD biomarker changes. Higher baseline 
plasma homocysteine was associated with faster rates of 
decline in global cognition, with and without accounting for 
lifestyle and biomarker measures (p=0.048). None of the 
lifestyle variables were associated with cognition.
Conclusions Diet influenced brain glucose metabolism 
in middle-aged participants, while plasma homocysteine 
explained variability in cognitive performance. These 
findings suggest that these modifiable risk factors affect 
AD risk through different pathways and support further 
investigation of risk reduction strategies in midlife.
IntrODuCtIOn 
Unless effective strategies for prevention are 
found, the prevalence of Alzheimer’s disease 
(AD), the most common form of dementia 
that affects nearly 34 million people world-
wide, is expected to triple by 2050.1 
Leading a healthy lifestyle in combination 
with strategies to reduce vascular disease risk 
is increasingly viewed as preventative against 
cognitive decline and dementia.2 Findings 
from population-attributable risk models esti-
mate that one in every three AD cases may 
be accounted for by modifiable risk factors, 
strengths and limitations of this study
 ► A key strength of this study is the availability of 
healthy, cognitively normal middle-aged individuals 
with multiple lifestyle and vascular risk measures 
and neuroimaging scans at least 2 years apart.
 ► Another strength of our study was our ability to look 
at diet, intellectual and physical activity and vascular 
risk factors and our statistical model enabled us to 
assess these risk factors simultaneously.
 ► Given the participants were cognitively normal and 
between ages 30  and  60  years, it is unlikely that 
we would see substantial changes in amyloid bur-
den, an age-dependent phenomenon and associat-
ed cognitive changes without lifestyle enrichment 
strategies this early in life.
 ► We caution that we carefully screened the study 
participants to include healthy individuals without 
severe cardiac or cerebrovascular disease, which 
limits the generalisability of our results to the entire 
population.
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such as midlife hypertension, obesity, diabetes and several 
lifestyle factors.3 4
Most studies in this field have focused on the effects of 
lifestyle and cardiovascular factors on cognitive decline or 
incidence of dementia as outcome measures.5 However, 
there is evidence that AD pathophysiology develops up 
to 20 years upstream of cognitive symptoms,6 7 namely in 
midlife. As such, studies investigating biological markers 
of AD are needed to determine whether lifestyle and 
vascular risk impact the emergence and progression of 
brain AD endophenotype.
Studies involving older adults, with or without mild 
cognitive impairment, have found both positive and null 
associations between intellectual and physical activity 
and AD biomarkers.8–14 The mixed results of these 
studies may be due to not taking diet or vascular risk into 
account, and focusing on elderly populations. Of those 
that included cognitively normal, middle-aged individ-
uals, physical activity has been shown to attenuate age-re-
lated brain biomarker changes,15 and insulin resistance 
has been positively associated with cerebral hypometabo-
lism, atrophy and amyloid deposition16–18 and negatively 
related to regional cerebral blood flow.19 We observed 
that adherence to a Mediterranean diet (MeDi) was 
positively associated with MRI-based cortical thickness in 
middle-aged individuals at cross-section, after accounting 
for intellectual activity, physical activity and vascular risk 
measures.20
Herein, we present a 3-year multimodality brain 
imaging study aimed at assessing the association of 
multiple lifestyle and vascular risk factors with change 
in AD biomarkers, as measured by amyloid-beta (Aβ) 
deposition on 11C-PiB PET, glucose metabolism via 18F-
FDG PET and neurodegeneration via MRI, in a cohort 




Study participants were recruited from a longitudinal 
brain imaging study conducted at New York University 
(NYU) Langone School of Medicine and Weill Cornell 
Medical College (WCMC) between 2010 and 2016. The 
study aimed to examine risk factors for AD among clin-
ically and cognitively normal middle-aged adults. Details 
about the study design have previously been published.21 22 
Briefly, participants were derived from multiple commu-
nity sources, including individuals interested in research 
participation and family members and caregivers of 
impaired patients.
All participants received clinical, laboratory, neuropsy-
chological and brain imaging exams including MRI and 
FDG PET and PiB PET at baseline and at least 2 years 
later. To be included in this study, participants had to 
be aged 30–60 years at baseline, with education ≥12 
years, Clinical Dementia Rating=0, Global Deterioration 
Scale≤2, Mini Mental State Examination≥27, Hamilton 
Depression Scale <16 and normal cognitive test perfor-
mance for age and education.23 Those with past or 
current medical conditions that can affect brain structure 
or function (ie, cardiovascular disease, stroke, diabetes, 
head trauma, any neurodegenerative diseases, depres-
sion, hydrocephalus, intracranial mass and infarcts on 
MRI) and those taking psychoactive medications were 
excluded.
A family history of AD that included at least one first-de-
gree relative whose AD onset was after age 60 years was 
elicited using standardised questionnaires.22 Apolipo-
protein E (APOE) genotypes were determined using 
standard quantitative PCR procedures.22 Participants 
were grouped as positive versus negative family history, 
and as APOE4 carriers versus non-carriers. Participants 
with a family history of AD and/or APOE4 positivity were 
considered at increased risk for AD.
standard protocol approvals, registrations and patient 
consents
All participants provided informed consent to participate 
in this study.
Patient and public involvement
Patients and or public were not involved in the planning 
or execution of the study. Results were not disseminated 
to study participants.
Global cognition measure
The neuropsychological battery of tests was previously 
described.23 At both time points, we assessed three cogni-
tive domains from the following tests: memory (imme-
diate and delayed recall of a paragraph and immediate 
and delayed recall of paired associates), executive func-
tion (Wechsler Adult Intelligence Scale (WAIS) digit 
symbol substitution) and language (WAIS vocabulary).
We computed a global cognitive summary score by 
first z-scoring each measure within each domain and 
averaging each component of the three domains listed 
above. Global cognition, calculated as the average of the 
composite memory, executive function and language vari-
ables at each time point, was used as an outcome variable.
Vascular risk-related measures
Vascular risk factors included in the model were: a) body 
mass index (BMI); b) presence of hypertension, conserva-
tively based on either current antihypertensive treatment 
or blood pressure assessments; c) plasma cholesterol and/
or homocysteine, obtained after overnight fasting using 
standard laboratory procedures and d) insulin resistance, 
measured with the Quantitative Insulin Sensitivity Check 
Index (QUICKI)24 derived from fasting plasma insulin 
(via ELISA kit) and fasting plasma glucose, where lower 
QUICKI scores reflect greater insulin resistance.
Lifestyle variables
Dietary data regarding average food consumption over 
the prior year were obtained using the Harvard Willett 
semi-quantitative food frequency questionnaire.20 25 
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Briefly, food items were categorised into 30 food groups 
based on similarities in food and nutrient composition, 
and intake (g/day) of each food group was calculated 
by summing the intakes of food group items. For the 
construction of MeDi scores, we first regressed caloric 
intake and calculated the derived residuals of daily intake 
for each of the following categories: dairy, meat, fruits, 
vegetables, legumes, cereals and fish. Individuals were 
assigned a value of one for each beneficial component 
(fruits, vegetables, legumes, cereals and fish) whose 
consumption was at or above the sex-specific median; 
a value of one for each harmful component (meat and 
dairy products) whose consumption was below the 
median; a value of one for a ratio of monounsaturated 
fats to saturated fats above the median and a value of one 
for mild-to-moderate alcohol consumption. These values 
were summed to generate a MeDi score, with a higher 
score indicating higher MeDi adherence.
The Minnesota Leisure Time Physical Activity question-
naire was used to estimate physical activity.26 For each 
activity, information was collected on the frequency and 
duration of engagement, which was multiplied by an activ-
ity-specific intensity code indicating calorie expenditure. 
The activity-dependent scores were summed to obtain the 
overall intensity of physical activity per person during the 
last 12 months and converted to metabolic equivalents.
Intellectual activity throughout life was assessed using 
a validated 25-item interview in which participants were 
asked to report how often they engaged in common 
cognitively demanding activities with minimal depen-
dence on socioeconomic statuses, such as reading books 
or newspapers, writing letters or e-mails, going to the 
library and playing games, at different ages.14 27 Previous 
studies have described this instrument in detail and 
reported high internal consistency and positive associa-
tions of intellectual activity with educational and cogni-
tive performance.27
AD biomarkers
All subjects received MRI, PiB PET and FDG PET scans 
at least 2 years apart following standardised proce-
dures.21 28 29
Participants received 3T volumetric T1-MPRAGE scans 
at both time points. Freesurfer V.5.3 with a longitudinal 
processing pipeline was used to obtain entorhinal (EC) 
and posterior cingulate cortex (PCC) thickness on longi-
tudinal MRI scans.30 These regions of interest (ROIs) were 
chosen based on previous reports of AD-related and life-
style-related changes at the preclinical AD stages.20 31 Total 
intracranial volumes (TIV) were also estimated and used 
as a covariate.
PET images were acquired with PET/CT scanners oper-
ating in three-dimensional mode and analysed using a 
fully automated image-processing pipeline.32 33 Statistics 
on image voxel values were extracted from automatically 
labelled cortical regions of interest using the automated 
anatomic labelling atlas.34 We selected PCC/precuneus as 
the target AD-related region of interest and frontal cortex 
(including prefrontal and medial frontal regions) as the 
target ageing-related region.35 For each region of interest, 
PiB uptake was divided by cerebellar grey matter uptake, 
and FDG uptake was normalised by the global activity.
statistical analysis
Statistical analyses were performed using Stata, V.13. We 
conducted two types of analyses to examine the associ-
ations of age, sex, APOE4 genotype, lifestyle variables 
(diet, intellectual activity and physical activity) and 
vascular risk variables (BMI, plasma cholesterol, plasma 
homocysteine, hypertension and insulin resistance) with 
AD biomarkers and cognition.
The first analysis consisted of a partial correlation 
analysis to evaluate the direct associations between the 
predictors and dependent variables at baseline and 
over time. We estimated these associations using partial 
Pearson’s correlations (rs) and adjusted for the effects 
of age, gender and APOE status. The PIB variables had 
skewed distributions and were log transformed, and MRI 
measures were adjusted by TIV.
In the second analysis, we used regressed change 
models36 to evaluate lifestyle and vascular measures as 
predictors of change in biomarker values and global 
cognition. Regressed change models, as opposed to differ-
ence score models, overcome several of the disadvantages 
of difference score measures.36 For example, difference 
scores are often negatively correlated with baseline values 
and are doubly affected by unreliability and missing data 
points in the measures.
We considered continuous variables including age 
(years), education (years), diet, exercise and intellectual 
activity scores, BMI, QUICKI scores and lab measures. Sex 
(female vs male) and APOE genotype (presence of either 
one or two vs absence of ε4 alleles) were used as dichot-
omous variables with female sex and APOE4 positivity as 
the reference. Presence or absence of hypertension was 
used as a dichotomous variable with the absence of the 
condition used as the reference.
In each model, we predicted regressed change in each 
outcome measure by running a series of regression models 
that isolated the effect of our predictors on the outcome 
measure at follow-up while holding the baseline measures 
constant. Additionally, the baseline biomarker measures 
were examined as predictors of change in cognition in 
addition to the other predictors. For each model, we used 
a backward elimination procedure to remove non-signif-
icant covariates and form the most parsimonious model.
We fit four separate models for each outcome measure:
 ► Model 1: full model with all predictor variables 
included.
 ► Model 2: full model with non-significant adjustment 
variables removed.
 ► Model 3: reduced model with lifestyle predictors only, 
and non-significant adjustment variables removed.
 ► Model 4: reduced model with vascular predictors only, 
and non-significant adjustment variables removed.
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The resulting unstandardised beta-coefficients (βs) can 
be interpreted as partial correlations. All results were 
considered statistically significant at p<0.05.
resuLts
Participants
A total of 86 participants completed baseline imaging eval-
uations. Six participants did not complete the follow-up 
evaluations. Of the remaining 80 participants, 10 had 
incomplete lifestyle questionnaires and were excluded. The 
remaining 70 participants were examined in this study.
Participants’ characteristics are shown in table 1. The 
average age was 49 years, ranging from 30 to 60 years, 
with 69% of participants being women. While none of 
the participants had cognitive impairment, 69% reported 
subjective memory complaints, as determined using the 
Global Deterioration Scale.37 Sixty-seven per cent of 
participants reported a family history of AD and 39% had 
at least one copy of the APOE4 allele.
Models for prediction of cognitive changes
None of the adjustment variables were associated with 
cognition at baseline or longitudinally. At baseline, higher 
intellectual activity was associated with better cognition, 
with and without adjusting for age, sex and APOE status 
(rs≥0.401, p<0.01; online supplementary etables 1-3).
Longitudinal results are summarised in table 2. After 
accounting for baseline cognition, higher baseline 
plasma homocysteine was associated with faster rates of 
decline in global cognition scores (p=0.048). None of 
the lifestyle variables were directly associated with cogni-
tive changes.
The baseline biomarkers did not predict cognitive 
changes, except for a negative non-significant association 
between baseline FDG uptake in the frontal cortex and 
faster rates of declines in global cognition (p=0.11). There-
fore, including the baseline biomarkers in the models did 
not significantly shift the relationships between cognition 
and the lifestyle or vascular variables.
Models for prediction of amyloid accumulation
Baseline results are summarised in online supplementary 
etable 1. None of the clinical, lifestyle or vascular risk vari-
ables were associated with baseline PiB uptake.
Longitudinal results are summarised in table 3. APOE4 
status was marginally positively associated with faster rates 
of amyloid deposition in the frontal cortex (p=0.084). 
None of the other vascular variables were associated with 
changes in amyloid measures.
Physical activity was marginally negatively associated 
with faster rates of amyloid changes in the PCC (p≤0.106), 
while MeDi adherence was marginally negatively associ-
ated with amyloid changes in the frontal cortex in models 
accounting for lifestyle and vascular factors (p≤0.104).
Models for prediction of FDG changes
Baseline results are summarised in online supplemen-
tary etable 2. Among the lifestyle variables, frontal FDG 
uptake was positively associated with intellectual activity 
(rs=0.27, p=0.042). None of the vascular variables showed 
associations with baseline FDG uptake.
Longitudinal results are summarised in table 4. Older 
age was marginally associated with increased rates of FDG 
declines in the frontal cortex (p=0.091), although not in 
the PCC. None of the other clinical variables were asso-
ciated with changes in FDG uptake. With and without 
accounting for baseline FDG uptake, lower MeDi adher-
ence was associated with faster rates of FDG declines in 
the PCC (p≤0.048) and marginally in the frontal cortex 
(p≤0.106). None of the vascular variables were associated 
with FDG changes.
Table 1 Clinical and demographic characteristic at 
baseline
Sample size (n) 70
Age (years) 49 (8), range 
30–60
Female, no. (%) 48 (69)
Education (years) 16 (2)
Caucasians, no. (%) 56 (80)
Positive family history of AD, no. (%) 47 (67)
APOE4 carriers, no. (%) 27 (39)
Positive subjective complaints, no. (%) 48 (69)
Time to follow-up (years) 3 (1), range 2–3.5
Lifestyle measures
  Mediterranean diet scores 4 (2), range 1–9
  Physical activity scores 9 (5), range 1–37
  Intellectual activity scores 4 (1), range 2–5
Vascular risk measures
  Body mass index (kg/m2) 25 (4)
  Presence of hypertension, no. (%) 10 (14)
  QUICKI scores 0.32 (0.03)
  Plasma cholesterol/HDL ratio 3.3 (0.8)
  Plasma homocysteine (μmol/L) 7.9 (6.2)
Neuropsychological measures
  Mini Mental State Examination 29 (1)
  Paragraph Recall, immediate 7.2 (2.5)
  Paragraph Recall, delayed 9.8 (2.8)
  Paired Associates Recall, immediate 6.4 (2.5)
  Paired Associates Recall, delayed 7.3 (2.6)
  Object naming 55 (9)
  Design test 8.1 (2.3)
  Digit symbol substitution 66 (13)
  WAIS vocabulary 68 (8)
Values are presented as mean (SD), unless otherwise specified.
AD, Alzheimer’s disease; APOE, apolipoprotein E; QUICKI, 
Quantitative Insulin Sensitivity Check Index; WAIS, Wechsler Adult 
Intelligence Scale.
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Models for prediction of MRI changes
Baseline results are summarised in online supplementary 
etable 3. None of the clinical, lifestyle and vascular risk 
variables were associated with baseline MRI measures.
Longitudinal results are summarised in table 5. APOE4 
status showed a positive, non-significant association with 
faster EC thickness reduction (p=0.149). None of the 
other variables were associated with changes in MRI 
measures.
Discussion
The main findings of this study are as follows: (1) during 
middle age, MeDi adherence predicts changes in glucose 
metabolism detected via FDG PET, but not changes in 
amyloid deposition or cortical thickness, (2) baseline 
plasma homocysteine was the only predictor of cogni-
tive changes and (3) exercise and intellectual activity 
did not predict changes in AD biomarkers or cognition. 
As such, the present findings do not support an associ-
ation between physical or intellectual activity and brain 
AD biomarker changes in middle-aged participants, but 
do contribute support to diet and vascular risk factors 
playing a role instead.
MeDi adherence predicted changes in FDG PET 
hypometabolic biomarkers while accounting for possible 
risk factors such as age, sex, APOE status, vascular 
measures and physical and intellectual activity. Lower 
MeDi adherence was associated with faster rates of FDG 
declines in the PCC, an early site of cerebral glucose util-
isation decline in AD.35 Progressive PCC hypometabo-
lism is a well-established finding in at-risk individuals,21 38 
and accurately predicts the decline from mild cognitive 
impairment to AD.35 Our data suggest that the neuro-
protective effects of the MeDi may lie in its ability to 
preserve brain metabolic activity, which may in turn help 
delay the onset of cognitive impairment.39 Additionally, 
higher plasma homocysteine, a well-known risk factor for 
AD,40 41 predicted declines in cognition and also showed 
borderline associations with increased rates of metabolic 
decline.
Altogether, these data suggest that diet and homocyste-
ine-related vascular risk may influence brain ageing and 
AD through different, yet to some extent interconnected 
pathways. Hence, adopting a healthy diet, particularly the 
MeDi, in combination with vascular risk management in 
midlife might be protective against future AD.
Hypometabolic changes observed with FDG are 
believed to emerge downstream to Aβ accumulation.31 
While we did not find direct effects of lifestyle or vascular 
risk factors on Aβ pathology, lower MeDi adherence was 
marginally, although non-significantly, associated with 
faster rates of Aβ deposition. This suggests that the asso-
ciations between lower MeDi adherence and increased 
metabolic declines may be related to emerging Aβ plaque 
pathology and/or increasing soluble Aβ (which is unde-
tectable with PET).
Furthermore, Aβ deposition in plaques is an age-depen-
dent phenomenon, with 0% of cognitively normal individ-
uals aged between 45 and 49 years testing positive for Aβ, 
and just under 6% aged between 50 and 59 years testing 
positive for Aβ.42 Considering that all our participants 
Table 2 Prediction of changes in global cognition
Model 1* Model 2† Model 3‡ Model 4§ 
Mediterranean diet −0.012 (0.046) −0.013 (0.048) −0.029 (0.046)
Physical activity 0.001 (0.008) −0.001 (0.008) −0.004 (0.008)
Intellectual activity 0.089 (0.128) 0.044 (0.128) 0.103 (0.128)
Plasma homocysteine −0.068 (0.034) p=0.061 −0.063 (0.032) p=0.066 −0.066 (0.032) p=0.048
Plasma cholesterol 0.001 (0.002) 0.001 (0.002) 0.001 (0.002)
Body mass index 0.007 (0.014) 0.006 (0.014) 0.006 (0.014)
QUICKI scores 0.343 (3.965) 0.537 (3.813) 0.798 (3.837)
Hypertension −0.080 (0.117) −0.056 (0.118) −0.055 (0.117)
Global cognition at 
baseline
0.872 (0.132) p<0.001 0.827 (0.143) p<0.001 0.801 (0.146) p<0.001 0.842 (0.132) p<0.001
Sex −0.023 (0.078)
APOE status 0.104 (0.079)
Age 0.006 (0.012)
Time to follow-up −0.000 (0.000)
Constant −0.097 (0.654) −0.125 (0.620) 0.005 (0.068) −0.167 (0.621)
Values are presented as unstandardised beta-coefficients (SE). Only significant and marginally significant p values are reported in the table.
*Model 1: full model with all variables examined.
†Model 2: full model without non-significant adjustment variables.
‡Model 4: model with vascular variables only, and without non-significant adjustment variables.
§Model 3: model with lifestyle variables only, and without non-significant adjustment variables.
APOE, apolipoprotein E; QUICKI, Quantitative Insulin Sensitivity Check Index.
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were cognitively normal and between 30 and 60 years of 
age, very few (if any) would have had substantial amyloid 
burden, making this cohort an ideal population for 
testing primary prevention strategies.
As with other studies in asymptomatic at-risk individ-
uals,32 33 43 imaging biomarkers were not associated with 
cognitive measures, most likely because our participants 
were all cognitively normal and younger than 60 years at 
baseline. Previous studies have demonstrated that asso-
ciations between brain biomarkers and cognition are 
evident in clinical AD patients, such as those with clear 
brain pathology, but not among normal populations.44 A 
longer follow-up duration may allow for additional patho-
logical and cognitive changes to manifest. We performed 
an additional sensitivity analysis to test for associations 
between biomarkers and domain-specific changes in 
memory, attention and language, which left our conclu-
sions substantially unchanged (see online supplementary 
eappendix).
We did not find a significant statistical relationship 
between intellectual and physical activity and biomarker 
changes. There is mixed evidence for the role of physical 
activity on brain ageing. A recent randomised controlled 
trial showed that aerobic exercise interventions 
resulted in improved cardiorespiratory fitness, which 
in turn improved memory and reduced brain atrophy 
in the elderly.45 Animal models have also suggested 
that physical activity has the potential to alleviate tau 
Table 3 Prediction of PiB PET amyloid deposition
Model 1* Model 2† Model 3‡ Model 4§ 
PCC
  Mediterranean diet −0.017 (0.016) −0.018 (0.017) −0.011 (0.016)
  Physical activity −0.005 (0.003) p=0.106 −0.005 (0.003) −0.005 (0.003) p=0.096
  Intellectual activity 0.053 (0.053) 0.021 (0.052) 0.016 (0.051)
  Plasma homocysteine −0.013 (0.012) −0.006 (0.012) −0.010 (0.012)
  Plasma cholesterol −0.002 (0.001) −0.001 (0.001) −0.001 (0.001)
  Body mass index −0.004 (0.005) −0.005 (0.005) −0.006 (0.005)
  QUICKI scores −1.720 (1.550) −2.155 (1.581) −2.016 (1.575)
  Hypertension −0.048 (0.041) −0.026 (0.037) −0.019 (0.036)
  PCC PiB uptake at 
baseline
0.094 (0.238) 0.194 (0.259) 0.156 (0.261) 0.232 (0.252)
  Sex 0.020 (0.031)
  APOE status 0.042 (0.029)
  Age 0.007 (0.004)
  Time to follow-up 0.000 (0.000)
  Constant 0.394 (0.256) 0.465 (0.264) p=0.088 0.126 (0.028) p<0.001 0.447 (0.263) p=0.090
Frontal cortex
  Mediterranean diet −0.016 (0.011) p=0.104 −0.018 (0.011) p=0.102 −0.011 (0.011)
  Physical activity −0.000 (0.002) −0.001 (0.002) −0.001 (0.002)
  Intellectual activity 0.050 (0.036) 0.031 (0.036) 0.019 (0.036)
  Plasma homocysteine −0.001 (0.008) −0.001 (0.008) −0.002 (0.008)
  Plasma cholesterol −0.001 (0.001) −0.001 (0.001) −0.001 (0.001)
  Body mass index −0.001 (0.003) −0.001 (0.003) −0.001 (0.003)
  QUICKI scores −1.293 (1.008) −1.497 (1.012) −1.184 (1.001)
  Hypertension −0.005 (0.029) −0.005 (0.026) 0.001 (0.025)
  Frontal PiB uptake at 
baseline
0.000 (0.143) 0.003 (0.145) 0.001 (0.144) 0.026 (0.140)
  Sex 0.017 (0.019)
  APOE status 0.033 (0.019) p=0.084
  Age 0.000 (0.002)
  Time to follow-up −0.000 (0.000)
  Constant 0.234 (0.167) 0.256 (0.168) 0.010 (0.018) p<0.001 0.208 (0.166)
See legend to table 2. Only significant and marginally significant p values are reported in the table.
APOE, apolipoprotein E; PCC, posterior cingulate cortex; QUICKI, Quantitative Insulin Sensitivity Check Index.
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hyperphosphorylation.46 However, a previous longitu-
dinal study in non-demented elderly reported absent to 
minimal associations between physical and intellectual 
activity and brain AD biomarker changes.8 In our study, 
physical activity was only marginally negatively associ-
ated with PCC amyloid deposition. Since we did not find 
significant relationships between intellectual and phys-
ical activity and biomarker changes, we tested to see if 
we had adequate power to detect these associations (see 
online supplementary eappendix). Based on the sensi-
tivity analysis, we had adequate power to detect associa-
tions of interest, indicating that the null results are not 
necessarily attributable to methodology or sample size 
concerns.
Additionally, the null results in our cohort are consis-
tent with findings from large-scale, community-based 
studies in the elderly.8 9 Therefore, we offer that the 
strongest arguments of the study are the significant find-
ings that manifest themselves despite the above limita-
tions. That said, clinical trials are needed to test whether 
these lifestyle interventions may alter the rate of change 
in AD biomarkers and cognition. Recent clinical trials 
provided encouraging evidence that multimodal lifestyle 
and vascular risk interventions improve cognition in the 
elderly.47
Worth noting is that we assumed linearity in the rate of 
change in biomarkers and cognition, which is reasonable 
for short time frames, as in this 3-year study, but possibly 
Table 4 Prediction of FDG PET metabolic changes
Model 1* Model 2† Model 3‡ Model 4§ 
PCC
  Mediterranean diet 0.010 (0.005) p=0.050 0.010 (0.005) p=0.048 0.010 (0.005) p=0.043
  Physical activity −0.000 (0.001) −0.000 (0.001) −0.000 (0.001)
  Intellectual activity 0.005 (0.015) 0.004 (0.015) 0.004 (0.014)
  Plasma homocysteine 0.004 (0.004) 0.004 (0.003) 0.004 (0.004)
  Plasma cholesterol 0.000 (0.000) 0.000 (0.000) −0.000 (0.000)
  Body mass index −0.001 (0.001) −0.001 (0.001) −0.001 (0.001)
  QUICKI scores 0.165 (0.480) 0.184 (0.438) 0.049 (0.459)
  Hypertension 0.001 (0.013) 0.003 (0.011) −0.000 (0.011)
  PCC FDG uptake at 
baseline
0.573 (0.194) p=0.006 0.587 (0.183) p=0.002 0.566 (0.184) p=0.003 0.515 (0.184) p=0.004
  Sex −0.003 (0.010)
  APOE status 0.001 (0.008)
  Age 0.000 (0.001)
  Time to follow-up −0.000 (0.000)
  Constant 1.154 (0.080) p<0.001 1.154 (0.083) p<0.001 1.182 (0.007) p<0.001 1.173 (0.076) p<0.001
Frontal cortex
  Mediterranean diet −0.011 (0.007) −0.012 (0.007) p=0.106 −0.012 (0.007) p=0.072
  Physical activity 0.001 (0.001) 0.000 (0.001) 0.001 (0.001)
  Intellectual activity 0.010 (0.020) 0.008 (0.019) 0.005 (0.019)
  Plasma homocysteine 0.003 (0.005) 0.002 (0.005) 0.002 (0.005)
  Plasma cholesterol 0.001 (0.000) 0.000 (0.000) 0.001 (0.000)
  Body mass index 0.002 (0.002) 0.003 (0.002) 0.003 (0.002)
  QUICKI scores −0.116 (0.690) −0.100 (0.669) 0.102 (0.668)
  Hypertension 0.017 (0.018) 0.009 (0.015) 0.013 (0.015)
  Frontal FDG uptake at 
baseline
0.202 (0.112) p=0.093 0.239 (0.107) p=0.040 0.196 (0.104) p=0.085 0.235 (0.101) p=0.036
  Sex 0.007 (0.011)
  APOE status −0.006 (0.012)
  Age −0.001 (0.001) p=0.091
  Time to follow-up −0.000 (0.000)
  Constant 1.209 (0.114) p<0.001 1.197 (0.111) p<0.001 1.174 (0.010) p<0.001 1.166 (0.110) p<0.001
See legend to table 2. Only significant and marginally significant p values are reported in the table.
APOE, apolipoprotein E; PCC, posterior cingulate cortex; QUICKI, Quantitative Insulin Sensitivity Check Index. 
8 Walters MJ, et al. BMJ Open 2018;8:e023664. doi:10.1136/bmjopen-2018-023664
Open access 
different for more extended periods of observation. For 
instance, increasing pathological burden with age may 
cause acceleration in cognitive and biomarker changes. 
Also, due to the relatively small sample size, we did not 
examine interactions between the different biomarkers, 
which may be influenced by lifestyle and vascular risk 
factors.
We caution that lifestyle habits were self-reported, and 
as self-reported lifestyle questionnaires are vulnerable to 
error, this may have reduced our ability to detect addi-
tional associations between lifestyle factors and AD risk.
Lastly, while our results are pertinent to healthy, 
middle-aged research participants without severe 
cardiac or cerebrovascular disease, results may differ 
in the elderly, in patients with dementia and in those 
with vascular or metabolic diseases. Studies with larger 
samples and longer follow-up times are needed to assess 
the generalisability of these findings in community-based 
populations with a higher variability in socioeconomic 
and medical status.
Our study has a number of strengths. While previous 
studies focused on elderly with no dementia, including 
those with cognitive impairment, this longitudinal 
biomarker study focused on cognitively intact, middle-
aged individuals. There is a consensus that lifestyle 
interventions have the highest chances of success when 
Table 5 Prediction of MRI-based cortical thickness change
Model 1* Model 2† Model 3‡ Model 4§ 
Entorhinal cortex
  Mediterranean diet 0.061 (0.042) 0.049 (0.042) 0.061 (0.040)
  Physical activity −0.010 (0.008) −0.009 (0.008) −0.008 (0.008)
  Intellectual activity −0.180 (0.112) −0.110 (0.111) −0.120 (0.106)
  Plasma homocysteine 0.012 (0.029) 0.012 (0.029) 0.006 (0.029)
  Plasma cholesterol −0.001 (0.002) −0.002 (0.002) −0.003 (0.002)
  Body mass index −0.000 (0.011) 0.001 (0.012) 0.003 (0.012)
  QUICKI scores 3.542 (4.008) 2.844 (4.075) 1.726 (4.345)
  Hypertension −0.035 (0.093) −0.072 (0.083) −0.088 (0.085)
  Entorhinal cortex 
thickness at baseline
0.407 (0.167) p=0.018 0.382 (0.168) p=0.025 0.361 (0.162) p=0.031 0.400 (0.157) p=0.012
  Sex 0.096 (0.079)
  APOE status −0.092 (0.064)
  Age −0.009 (0.008)
  Time to follow-up −0.0007 (0.0002)
  Constant 2.710 (0.654) p=0.001 2.784 (0.667) p=0.001 3.303 (0.059) p<0.001 2.956 (0.710) p<0.001
PCC
  Mediterranean diet 0.003 (0.016) 0.002 (0.015) 0.002 (0.015)
  Physical activity −0.002 (0.003) −0.002 (0.003) −0.001 (0.003)
  Intellectual activity −0.034 (0.047) −0.015 (0.045) −0.019 (0.041)
  Plasma homocysteine 0.009 (0.012) 0.008 (0.011) 0.009 (0.010)
  Plasma cholesterol −0.000 (0.001) −0.000 (0.001) −0.000 (0.001)
  Body mass index −0.002 (0.005) −0.001 (0.005) −0.001 (0.005)
  QUICKI scores 0.801 (1.643) 0.794 (1.577) 0.698 (1.581)
  Hypertension 0.052 (0.038) 0.037 (0.033) 0.035 (0.033)
  PCC thickness at 
baseline
0.390 (0.205) p=0.099 0.459 (0.209) p=0.050 0.508 (0.205) p=0.023 0.506 (0.182) p=0.011
  Sex 0.012 (0.032)
  APOE status −0.020 (0.028)
  Age −0.003 (0.004)
  Time to follow-up 0.000 (0.000)
  Constant 2.321 (0.267) p<0.001 2.311 (0.260) p<0.001 2.418 (0.024) p<0.001 2.326 (0.260) p<0.001
See legend to table 2. Only significant and marginally significant p values are reported in the table. All MRI models are adjusted for total 
intracranial volume (data not shown).
APOE, apolipoprotein E; PCC, posterior cingulate cortex; QUICKI, Quantitative Insulin Sensitivity Check Index. 
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implemented well before old age,5 making our results 
particularly relevant to efforts aimed at preventing AD.
Furthermore, the majority of previous studies looked 
at intellectual and physical activity, but not at diet. We 
demonstrated that diet does, in fact, influence the rate of 
change in metabolic AD biomarkers, whereas intellectual 
and physical activity do not appear to do so.
Lastly, our statistical model enabled us to simultane-
ously assess multiple lifestyle and vascular risk factors, 
yielding a more comprehensive understanding of the 
associations between these modifiable risk factors and AD 
risk. A combined reduction in several modifiable AD risk 
factors is projected to have a more significant impact than 
any one factor alone.4
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